DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.
DeuterOncology is a preclinical-stage biotechnology company dedicated to developing innovative cancer therapies. The company's primary focus is on a first-in-class dual MET and RAS pathway inhibitor, currently under investigation as a targeted treatment for lung cancer. This lead compound aims to enhance oncology treatment outcomes and may have broader applications when combined with standard of care and other targeted agents. By optimizing the therapeutic approach to cancer, DeuterOncology seeks to improve the effectiveness of treatment options available to medical professionals and ultimately benefit cancer patients.
ChromaCure will launch a drug development program to identify potential new candidates that selectively and potently inhibit cancer targets and potentially provide novel therapy for multiple forms of cancer, either as monotherapy or in combination with immunotherapy or chemotherapy.
Synergia Medical aims at developing and commercializing next generation neurostimulation devices. It relies on a seasoned management team with extensive experience in developing implantable neurostimulators.
In only three years time, the company became ISO13485 certified, created and sold an OEM external neurostimulator for a motorized amputee prosthesis arm and developed its first version of the NAOS platform.
Supported by private investors and public research grants, the company has quickly grown to a team of thirteen highly skilled multidisciplinary professionals.
DIM3 SA develops and markets clinical expert platforms and medical devices for clinical nutrition management. Its products include Scorso, an application for the screening and follow up of disease related malnutrition; Nutrow, a decision support software for an optimization of clinical nutrition; and Biocorder, a clinical mobile assistant medical box. The company was founded in 2013 and is headquartered in Beaufays, Belgium.